Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Rhythm Pharmaceuticals

04/08/2026 14:31

Rhythm Pharmaceuticals Inc RYTM.OQ reported a quarterly adjusted loss of 73 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -75 cents.  The mean expectation of sixteen analysts for the quarter was for a loss of 82 cents per share. Wall Street expected results to range from $-1.02 to -67 cents per share.
Revenue rose 46.9% to $71.26 million from a year ago; analysts expected $67.28 million. 
Rhythm Pharmaceuticals Inc's reported EPS for the quarter was a loss of 73 cents​.
The company reported a quarterly loss of $50.36 million.
Rhythm Pharmaceuticals Inc shares had fallen by 7.4% this quarter and lost 4.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Rhythm Pharmaceuticals Inc is $141.50, about 27.4% above its last closing price of $102.78
This summary was machine generated from LSEG data August 4 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.82
-0.73
Beat
Mar. 31 2026 
-0.85
-0.83
Beat
Dec. 31 2025 
-0.82
-0.73
Beat
Sep. 30 2025 
-0.72
-0.82
Missed